Savior Lifetec

Savior Lifetec EBIT Margin

The EBIT Margin (Operating Margin) of Savior Lifetec (4167.TWO) as of Oct 25, 2026 is 16.50 %. In the previous year, EBIT Margin (Operating Margin) was 9.77 % — a change of 68.90% (higher).

EBIT Margin

16.50 %

YoY

68.90%

Last updated:

EBIT Margin (Operating Margin) of Savior Lifetec is 2025 16.50 % . EBIT Margin (Operating Margin) of Savior Lifetec was 2024 9.77 % . It decreases by 68.90% higher compared to the previous year.

For Savior Lifetec, the operating (EBIT) margin of 16.5% is up versus 1.6% a few years ago.

The Savior Lifetec EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-31.71 TWD
Jan 1, 2019
2.59 TWD
Jan 1, 2020
15.71 TWD
Jan 1, 2021
1.57 TWD
Jan 1, 2022
4.11 TWD
Jan 1, 2023
-0.23 TWD
Jan 1, 2024
9.77 TWD
Jan 1, 2025
16.50 TWD
The Savior Lifetec EBIT Margin history
YEAREBIT MarginYoY
16.50 %+68.90%
9.77 %-4,339.00%
-0.23 %-105.61%
4.11 %+162.23%
1.57 %-90.03%
15.71 %+506.10%
2.59 %-108.17%
-31.71 %-1,143.46%
3.04 %-127.10%
-11.21 %-72.88%
-41.35 %+26.58%
-32.66 %+14,576.49%
-0.22 %-58.08%
-0.53 %+40.33%
-0.38 %+22.92%
-0.31 %-47.85%
-0.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

EBIT Margin (Operating Margin) of Savior Lifetec is 16.50 % in 2025.

EBIT Margin (Operating Margin) of Savior Lifetec changed from 9.77 % to 16.50 %, representing a 68.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Savior Lifetec with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Savior Lifetec

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Savior Lifetec